| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5734816 | Surgery | 2017 | 10 Pages |
Abstract
The survival impact of neoadjuvant therapy is stage-dependent. Neoadjuvant therapy does not disadvantage survival compared with conventional upfront surgery followed by adjuvant therapy in any stage, and is associated with a significant survival advantage in stage III pancreatic cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
Susanna W.L. BS, Mariam F. MD, MPH, Lindsay A. MD, MPH, Gyulnara G. MD, Sing Chau MS, Mark P. MD, Jennifer F. MD, MPH,